BioPharma-Reporter | Nachrichten

Zeit	Aktuelle Nachrichten
Fr	Orchard to build $80m gene therapy manufacturing facility
Do	Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
Do	Hired and retired: Year's end edition
Mi	Cambrex continues build-out at former PharmaCore site with $1m investment
Mi	Chinese firm plans 'first-in-class' biologics after $325m manufacturing investment
Mi	Insulin biosimilars? US FDA readies market for entry
Di	Biotage acquires Phynexus in $21.5m deal
Di	Lonza and GE look to China with development of biologics facility
Mo	Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO
07.12.	WuXi Biologics: Ireland's largest single-use facility underway
07.12.	UK-funded study to investigate patients' experience of cell and gene therapies
06.12.	Tech focus: Making waves with acoustic separation in cell processing
05.12.	Leukemia licensing deal could potentially cost Janssen more than $1.8bn
05.12.	Catalent expands biologics facility, to create 36 new jobs
05.12.	Leukemia licensing deal may cost Janssen more than $1.3bn
05.12.	Start-up develops cell replacement therapy to 'make hair loss history'
04.12.	Samsung BioLogics CEO responds to regulator's accountancy claims
04.12.	AbbVie secures another Humira patent deal
30.11.	Five big pharma deals in Humira market could save UK £300m
30.11.	Bayer to shed €600m factor VIII facility and 12,000 staff
30.11.	Celltrion and Teva announce first Rituxan biosimilar approval in US
29.11.	WuXi Biologics wins ABL Bio contract for bispecific antibodies
28.11.	Giving patients a choice: Genentech RA auto-injector product approved in US
28.11.	Pall, Cobra and CGTC collaborate on continuous method for gene therapies
27.11.	UK vows to speed up drug review in return for 2% sales cap

Zeit

Aktuelle Nachrichten

Orchard to build $80m gene therapy manufacturing facility

Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency

Hired and retired: Year's end edition

Cambrex continues build-out at former PharmaCore site with $1m investment

Chinese firm plans 'first-in-class' biologics after $325m manufacturing investment

Insulin biosimilars? US FDA readies market for entry

Biotage acquires Phynexus in $21.5m deal

Lonza and GE look to China with development of biologics facility

Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

07.12.

WuXi Biologics: Ireland's largest single-use facility underway

07.12.

UK-funded study to investigate patients' experience of cell and gene therapies

06.12.

Tech focus: Making waves with acoustic separation in cell processing

05.12.

Leukemia licensing deal could potentially cost Janssen more than $1.8bn

05.12.

Catalent expands biologics facility, to create 36 new jobs

05.12.

Leukemia licensing deal may cost Janssen more than $1.3bn

05.12.

Start-up develops cell replacement therapy to 'make hair loss history'

04.12.

Samsung BioLogics CEO responds to regulator's accountancy claims

04.12.

AbbVie secures another Humira patent deal

30.11.

Five big pharma deals in Humira market could save UK £300m

30.11.

Bayer to shed €600m factor VIII facility and 12,000 staff

30.11.

Celltrion and Teva announce first Rituxan biosimilar approval in US

29.11.

WuXi Biologics wins ABL Bio contract for bispecific antibodies

28.11.

Giving patients a choice: Genentech RA auto-injector product approved in US

28.11.

Pall, Cobra and CGTC collaborate on continuous method for gene therapies

27.11.

UK vows to speed up drug review in return for 2% sales cap

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von BioPharma-Reporter